Fig. 5
From: Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy
Anti-PD-L1 antibody therapeutic effect on inflammation reduction is associated with the T-cell chemoattractant Cxcl12. This experiment included three groups of DM-hTAU mice treated either with: IgG, αPD-L1, or αCCR2 + αPD-L1. αCCR2 was i.p. injected to DM-hTAU mice 3 days prior (Day − 3) to αPD-L1 (Day 0), and again on days 1, 5 and 9. Hippocampi were excised and analyzed by RT-qPCR 3 days after the last αCCR2 injection (Day 12). (A) RT-qPCR results for Cxcl12 (One-way ANOVA F(2,15) = 6.3419, **p = 0.0097), (B) Tnfα (One-way ANOVA F(2,15) = 2.095, p = 0.1576), (C) Il-1β (One-way ANOVA F(2,15) = 1.821, p = 0.1959), (D) Il-6 (One-way ANOVA F(2,15) = 5.958, *p = 0.0125), and (E) Il-12p35 (One-way ANOVA F(2,15) = 3.607, p = 0.0526). (A-E) Post-hoc uncorrected Fisher’s LSD multiple comparisons between the groups: *p < 0.05, **p < 0.01; n = 6 mice per group. Data are presented as mean ± s.e.m. (F) Pearson correlation coefficient tests revealed significant linear correlations between the measured mRNA levels of Cxcl12 and of the inflammatory cytokines: Tnfα (r(Pearson) = 0.65, **p = 0.0035), (G) Il-1β (r(Pearson) = 0.734, ***p < 0.001), (H) Il-6 (r(Pearson) = 0.636, **p = 0.0046), and (I) Il-12p35 (r(Pearson) = 0.818, ***p < 0.0001)